Dear [enter recipient name],

My name is [Name], a representative for Azurity Pharmaceuticals, specializing in pediatric medicine.

I wanted to let you know that Xatmep® (methotrexate) oral solution is available for your patients with Acute Lymphoblastic Leukemia. It is also the first and only FDA-approved oral solution that is available.

Xatmep may benefit your patients:
- 2.5mg/mL provides easy dose titration as body surface area-based dosing is recommended.
- Ready-to-use Oral Solution with a sweet taste.
- Designed for the patient who is unable to swallow a tablet or has a fear of needles and prefers not to receive a shot.
- Provides patient convenience of being stable with options of being stored at room temperature for up to 60 days or refrigerated through the expiration date on the label.

I would like 10 minutes of your time to discuss Xatmep.

Thank you,

[INSERT YOUR NAME]
[INSERT YOUR TITLE]
WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY

See full prescribing information for complete boxed warning.

Methotrexate can cause the following severe or fatal adverse reactions. Monitor closely and modify dose or discontinue methotrexate as appropriate.

- Bone marrow suppression [see Warnings and Precautions (5.1)]
- Serious infections [see Warnings and Precautions (5.2)]
- Renal toxicity and increased toxicity with renal impairment [see Warnings and Precautions (5.3)]
- Gastrointestinal toxicity [see Warnings and Precautions (5.4)]
- Hepatic toxicity [see Warnings and Precautions (5.5)]
- Pulmonary toxicity [see Warnings and Precautions (5.6)]
- Hypersensitivity and dermatologic reactions [see Warnings and Precautions (5.7)]
- Methotrexate can cause embryo-fetal toxicity, including fetal death. Use in pJIA is contraindicated in pregnancy. Consider the benefits and risks of XATMEP and risks to the fetus when prescribing XATMEP to a pregnant patient with a neoplastic disease. Advise females and males of reproductive potential to use effective contraception during and after treatment with XATMEP [see Contraindications (4), Warnings and Precautions (5.9), Use in Specific Populations (8.1, 8.3)].

INDICATIONS

Xatmep is a folate analog metabolic inhibitor indicated for the:

- treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen.
- management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

For Full Prescribing Information of Xatmep, please click here: Full Prescribing Information

For more information on Xatmep, please click here: Xatmep Website

XTM-27

Azurity Pharmaceuticals | 841 Woburn St., Wilmington, MA 01887 | Azurity.com

© 2020 Azurity Pharmaceuticals™ Inc. All rights reserved.
Azurity Pharmaceuticals™, Inc. is the parent company of Silvergate Pharmaceuticals, Inc. Labeling may reflect either name.

UNSUBSCRIBE | PRIVACY | CONTACT US